Clinical Trials

Biomarkers/Imaging      

Prognostic Significance of Circulating Tumor Cells in Patients with Renal Cell Carcinoma
Principal Investigator: Vitaly Margulis, M.D.
Status: Recruiting
Contact: Allison Beaver, R.N.
Phone: 214-645-8787
Allison.Beaver@UTSouthwestern.edu

Multiparametric MRI in T1b-T4 Renal Masses
Principal Investigator: Ivan Pedrosa, M.D., Ph.D.
Status: Recruiting
Contact: Michael Fulkerson
Phone: 214-648-5984
Michael.Fulkerson@UTSouthwestern.edu

Advanced MR Imaging in the Characterization of Renal Cell Carcinoma: Correlation with Pathology and Gene Expression Profiles
Principal Investigator: Ivan Pedrosa, M.D., Ph.D.
Status: Recruiting
Contact: Michael Fulkerson
Phone: 214-648-5984
Michael.Fulkerson@UTSouthwestern.edu

Localized RCC

Success of Active Surveillance in Patients with Untreated Small Renal Masses with the Option of Delayed Treatment
Principal Investigator: Vitaly Margulis, M.D.
Status: Recruiting
Contact: Allison Beaver, R.N.
Phone: 214-645-8787
Allison.Beaver@UTSouthwestern.edu

A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients with Primary Renal Cell Carcinoma (RCC) 
Clinical Trials.gov ID: NCT02141919
Principal Investigator: Raquibul Hannan, M.D., Ph.D.
Status: Recruiting
Contact: Samantha Mannala
Phone: 214-648-1873
Samantha.Mannala@UTSouthwestern.edu 

Safety Lead-in Phase II Trial of Neo-Adjuvant SABR for IVC Tumor Thrombi in Newly Diagnosed RCC
Clinical Trials.gov ID: NCT02473536
Principal Investigator: Raquibul Hannan, M.D., Ph.D.
Status: Recruiting
Contact: Samantha Mannala
Phone: 214-648-1873
Samantha.Mannala@UTSouthwestern.edu 

Neoadjuvant

A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER)
Clinical Trials.gov ID: NCT03055013
Principal Investigator: Vitaly Margulis, M.D.
Status: Recruiting
Contact: Allison Beaver, R.N.
Phone: 214-645-8787
Allison.Beaver@UTSouthwestern.edu

Adjuvant

A Phase III Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (anti-PD-L1 antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Clinical Trials.gov ID: 
NCT03024996
Principal Investigator: James Brugarolas, M.D., Ph.D.
Status: Recruiting
Contact: Dendra Von Merveldt, R.N.
Phone: 214-648-8787
Dendra.Vonmerveldt@UTSouthwestern.edu

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab in Adjuvant RCC (KEYNOTE-564)
Clinical Trials.gov ID: NCT03142334
Principal Investigator: Hans Hammers, M.D., Ph.D.
Status: Pending Review
Contact: Allison Beaver, R.N.
Phone: 214-645-8787
Allison.Beaver@UTSouthwestern.edu

Advanced RCC - No Prior Treatment

A Phase II Trial of Stereotactic Body Radiation Therapy in Combination with Nivolumab plus Ipilumimab in Patients with Metastatic Renal Cell Cancer 
Clinical Trials.gov ID: NCT03065179
Principal Investigator: Hans Hammers, M.D., Ph.D.

Status: Recruiting
Meet a patient on this trial.
Contact: Allison Beaver, R.N.
Phone: 214-645-8787
Allison.Beaver@UTSouthwestern.edu

A Phase II Study of Front-line Therapy with Nivolumab and Salvage Nivolumab plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma 
Principal Investigator: Hans Hammers, M.D., Ph.D.
Status: About to Open
Contact: Allison Beaver, R.N.
Phone: 214-645-8787
Allison.Beaver@UTSouthwestern.edu

Phase II Trial of SABR for Patients with Oligometastatic Renal Cell Carcinoma
Clinical Trials.gov ID: NCT02956798
Principal Investigator: Raquibul Hannan, M.D., Ph.D.
Status: Recruiting 
Contact: Samantha Mannala
Phone: 214-648-1873
Samantha.Mannala@UTSouthwestern.edu 

Advanced RCC - Prior Treatment

Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma
ClinicalTrials.gov ID: NCT02781506
Principal Investigator: Raquib Hannan, M.D., Ph.D.

Status: Recruiting
Contact: Samantha Mannala
Phone: 214-648-1873
Samantha.Mannala@UTSouthwestern.edu

Phase II Trial of Stereotactic Ablative Radiation Therapy (SAbR) for Oligoprogressive Clear Cell Renal Cell Carcinoma
ClinicalTrials.gov ID: NCT03696277 
Principal Investigator: Raquib Hannan, M.D., Ph.D.

Status: Recruiting
Contact: Samantha Mannala
Phone: 214-648-1873
Samantha.Mannala@UTSouthwestern.edu

Phase I/II Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination with Epacadostat (INCB024360) in Subjects with Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037 / ECHO-202)
Clinical Trials.gov ID: NCT02178722
Principal Investigator: Aravind Sanjeevaiah, M.D.

Status: Recruiting
Contact: Pamela Kurian, M.S.
Phone: 214-648-5874
pamela.kurian@utsouthwestern.edu 

Advanced RCC - Prior PD1/PDL1

A Phase 1 and 2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with NKTR-214 and in Combination with NKTR-214 Plus Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
Clinical Trials.gov ID: NCT03435640 
Principal Investigator: James Brugarolas, M.D., Ph.D.
Status: Recruiting
Contact: Oluwatomilade Fatunde
Phone: 214-648-4972
Oluwatomilade.Fatunde@UTSouthwestern.edu

Phase I/Ib Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Clinical Trials.gov ID: NCT02655822
Principal Investigator: Kevin Courtney, M.D., Ph.D.

Status: Recruiting
Contact: Nour Sukar
Phone: 214-648-5107
Nour.Sukar@UTSouthwestern.edu

Phase II BMS FRACTION Study to Test Combination Treatments
Principal Investigator: Hans Hammers, M.D., Ph.D.
Status: Pending Review
Contact: Allison Beaver, R.N.
Phone: 214-645-8787
Allison.Beaver@UTSouthwestern.edu